CAD 106

Drug Profile

CAD 106

Alternative Names: Alzheimer's disease vaccine (CAD106) - Kuros Biosciences/GlaxoSmithKline; CAD106; Immunodrug™ for Alzheimer's disease - Kuros Biosciences/GlaxoSmithKline

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Cytos Biotechnology
  • Developer GlaxoSmithKline
  • Class Alzheimer vaccines; Antidementias; Neuroprotectants
  • Mechanism of Action Amyloid beta-protein inhibitors; Immunomodulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Alzheimer's disease
  • Discontinued Hypersensitivity; Rheumatoid arthritis

Most Recent Events

  • 13 Jun 2016 Phase-II/III clinical trials in Alzheimer's disease in Belgium and Finland (IM) (EudraCT2015-002715-15)
  • 22 Dec 2015 Phase-II/III clinical trials in Alzheimer's disease in USA (IM) (NCT02565511)
  • 02 Sep 2015 CAD 106 is still in phase-II development for Alzheimer's disease in North America and Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top